Pro Medicus Ltd
ASX:PME

Watchlist Manager
Pro Medicus Ltd Logo
Pro Medicus Ltd
ASX:PME
Watchlist
Price: 251.63 AUD -0.08%
Market Cap: 26.3B AUD

Intrinsic Value

The intrinsic value of one PME stock under the Base Case scenario is 41.66 AUD. Compared to the current market price of 251.63 AUD, Pro Medicus Ltd is Overvalued by 83%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PME Intrinsic Value
41.66 AUD
Overvaluation 83%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Pro Medicus Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about PME?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is PME valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Pro Medicus Ltd.

Explain Valuation
Compare PME to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Heightened competition from larger healthcare IT players could erode Pro Medicus’s pricing power and disrupt its pipeline of long-term contracts, especially in the heavily contested U.S. hospital market.

Reliance on a few marquee contracts, including sizeable deals with major hospital networks, poses revenue-concentration risk. Any failure to renew or expand these key partnerships could materially impact the firm’s top line.

Regulatory hurdles and prolonged sales cycles in new geographic regions could delay client onboarding, driving up costs and extending the time needed to realize meaningful returns on international expansion initiatives.

Bull Theses

Pro Medicus’s cloud-based imaging software offers faster performance and greater scalability than most legacy systems, giving it a strong competitive advantage in winning high-margin, multi-year contracts with top-tier healthcare providers.

The company has demonstrated consistent growth in recurring revenue tied to usage-based licensing fees, reflecting robust adoption rates and strong stickiness among its existing hospital networks in the U.S. and Europe.

An agile research and development approach, supported by a debt-free balance sheet, enables Pro Medicus to quickly incorporate emerging technologies like AI-driven analytics, expanding its service offerings and creating additional revenue streams.

Show More Less
How do you feel about PME?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Pro Medicus Ltd

Current Assets 280.1m
Cash & Short-Term Investments 209.2m
Receivables 65.5m
Other Current Assets 5.4m
Non-Current Assets 58.6m
Long-Term Investments 7.3m
PP&E 2.8m
Intangibles 20.8m
Other Non-Current Assets 27.7m
Current Liabilities 43.1m
Accounts Payable 1.4m
Other Current Liabilities 41.7m
Non-Current Liabilities 38.6m
Long-Term Debt 1.6m
Other Non-Current Liabilities 37m
Efficiency

Free Cash Flow Analysis
Pro Medicus Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Pro Medicus Ltd

Revenue
220.5m AUD
Cost of Revenue
-309k AUD
Gross Profit
220.2m AUD
Operating Expenses
-55m AUD
Operating Income
165.2m AUD
Other Expenses
-50m AUD
Net Income
115.2m AUD
Fundamental Scores

PME Profitability Score
Profitability Due Diligence

Pro Medicus Ltd's profitability score is 88/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROIC
Exceptional 3Y Average ROE
Exceptional ROIC
Exceptional ROE
88/100
Profitability
Score

Pro Medicus Ltd's profitability score is 88/100. The higher the profitability score, the more profitable the company is.

PME Solvency Score
Solvency Due Diligence

Pro Medicus Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Pro Medicus Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PME Price Targets Summary
Pro Medicus Ltd

Wall Street analysts forecast PME stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PME is 333.02 AUD with a low forecast of 292.9 AUD and a high forecast of 367.5 AUD.

Lowest
Price Target
292.9 AUD
16% Upside
Average
Price Target
333.02 AUD
32% Upside
Highest
Price Target
367.5 AUD
46% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for PME is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one PME stock?

The intrinsic value of one PME stock under the Base Case scenario is 41.66 AUD.

Is PME stock undervalued or overvalued?

Compared to the current market price of 251.63 AUD, Pro Medicus Ltd is Overvalued by 83%.

Back to Top